Substituted Triazoles as mGluR5 Allosteric Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing selective mGluR5 agonists that can effectively penetrate the CNS and demonstrate in vivo activity has been challenging due to the high conservation of the glutamate binding site among mGluR family members, making it difficult to treat neurological and psychiatric disorders associated with NMDA receptor hypofunction.
Innovation Solution
Design and synthesis of substituted triazole derivatives that act as positive allosteric modulators of the mGluR5 receptor, binding to an allosteric site rather than the orthosteric glutamate binding site, thereby modulating receptor activity without interfering with natural glutamate signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If agonists bind to the orthosteric glutamate binding site of mGluR5, then receptor activation is achieved, but selectivity among mGluR family members is lost due to high conservation of the binding site
Solution Approach 1:
The patent employs an allosteric binding site as an intermediary location that indirectly modulates mGluR5 activation. Instead of directly competing at the conserved orthosteric site, the compound binds to a distinct allosteric pocket, using this intermediate location to achieve both selectivity and functional modulation of the receptor
Solution Approach 2:
The invention transitions from binding at the traditional orthosteric site (one dimension of interaction) to binding at an allosteric site (another dimension of interaction). This dimensional shift in binding location allows the compound to achieve selectivity while still influencing receptor activation through a different spatial pathway
2Reliability
If selective mGluR5 agonists are developed, then in vivo activity may be achieved, but CNS penetration remains challenging
Solution Approach 1:
The patent modifies molecular parameters of the triazole compounds, including lipophilicity, molecular weight, and structural features, to optimize the balance between CNS penetration and in vivo activity. These parameter adjustments allow the compounds to cross the blood-brain barrier while maintaining selective mGluR5 modulation
3Reliability
If compounds are designed to modulate mGluR5 activity, then NMDA receptor signaling can be normalized, but off-target effects on other receptors must be avoided
Solution Approach 1:
The patent applies local quality by designing the triazole compound to interact specifically with the unique structural features of the mGluR5 allosteric site. The compound's molecular structure is optimized to fit this specific local environment, ensuring that modulation occurs only at mGluR5 without affecting other receptors with different binding site architectures
Data Source
AI summary
This invention relates to compounds of formula (I), their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3 have meanings given in the description.